vs
Side-by-side financial comparison of Celanese Corp (CE) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Celanese Corp is the larger business by last-quarter revenue ($2.2B vs $1.1B, roughly 2.0× PERRIGO Co plc). Celanese Corp runs the higher net margin — 0.6% vs -127.8%, a 128.4% gap on every dollar of revenue. On growth, PERRIGO Co plc posted the faster year-over-year revenue change (-2.5% vs -7.0%). Celanese Corp produced more free cash flow last quarter ($168.0M vs $148.6M). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -8.1%).
Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
CE vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $1.1B |
| Net Profit | $14.0M | $-1.4B |
| Gross Margin | 19.1% | 32.6% |
| Operating Margin | 4.0% | -116.0% |
| Net Margin | 0.6% | -127.8% |
| Revenue YoY | -7.0% | -2.5% |
| Net Profit YoY | 100.7% | -3093.9% |
| EPS (diluted) | $0.13 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $1.1B | ||
| Q3 25 | $2.4B | $1.0B | ||
| Q2 25 | $2.5B | $1.1B | ||
| Q1 25 | $2.4B | $1.0B | ||
| Q4 24 | $2.4B | $1.1B | ||
| Q3 24 | $2.6B | $1.1B | ||
| Q2 24 | $2.7B | $1.1B | ||
| Q1 24 | $2.6B | $1.1B |
| Q4 25 | $14.0M | $-1.4B | ||
| Q3 25 | $-1.4B | $7.5M | ||
| Q2 25 | $199.0M | $-8.4M | ||
| Q1 25 | $-21.0M | $-6.4M | ||
| Q4 24 | $-1.9B | $-44.4M | ||
| Q3 24 | $116.0M | $-21.0M | ||
| Q2 24 | $155.0M | $-108.4M | ||
| Q1 24 | $121.0M | $2.0M |
| Q4 25 | 19.1% | 32.6% | ||
| Q3 25 | 21.5% | 36.1% | ||
| Q2 25 | 21.1% | 34.4% | ||
| Q1 25 | 19.9% | 37.6% | ||
| Q4 24 | 22.7% | 33.9% | ||
| Q3 24 | 23.5% | 37.2% | ||
| Q2 24 | 24.2% | 37.0% | ||
| Q1 24 | 21.2% | 33.1% |
| Q4 25 | 4.0% | -116.0% | ||
| Q3 25 | -52.7% | 7.0% | ||
| Q2 25 | 9.2% | 4.3% | ||
| Q1 25 | 7.0% | 4.5% | ||
| Q4 24 | -59.3% | 10.0% | ||
| Q3 24 | 9.4% | 7.4% | ||
| Q2 24 | 9.4% | -2.5% | ||
| Q1 24 | 8.0% | -5.1% |
| Q4 25 | 0.6% | -127.8% | ||
| Q3 25 | -56.1% | 0.7% | ||
| Q2 25 | 7.9% | -0.8% | ||
| Q1 25 | -0.9% | -0.6% | ||
| Q4 24 | -80.8% | -3.9% | ||
| Q3 24 | 4.4% | -1.9% | ||
| Q2 24 | 5.8% | -10.2% | ||
| Q1 24 | 4.6% | 0.2% |
| Q4 25 | $0.13 | $-10.23 | ||
| Q3 25 | $-12.39 | $0.05 | ||
| Q2 25 | $1.81 | $-0.06 | ||
| Q1 25 | $-0.19 | $-0.05 | ||
| Q4 24 | $-17.50 | $-0.32 | ||
| Q3 24 | $1.06 | $-0.15 | ||
| Q2 24 | $1.41 | $-0.79 | ||
| Q1 24 | $1.10 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $11.4B | — |
| Stockholders' EquityBook value | $4.0B | $2.9B |
| Total Assets | $21.7B | $8.5B |
| Debt / EquityLower = less leverage | 2.81× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $432.1M | ||
| Q2 25 | — | $454.2M | ||
| Q1 25 | — | $409.9M | ||
| Q4 24 | — | $558.8M | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $542.8M | ||
| Q1 24 | — | $658.5M |
| Q4 25 | $11.4B | — | ||
| Q3 25 | $11.7B | — | ||
| Q2 25 | $12.7B | — | ||
| Q1 25 | $12.4B | — | ||
| Q4 24 | $11.1B | — | ||
| Q3 24 | $11.3B | — | ||
| Q2 24 | $11.1B | — | ||
| Q1 24 | $11.0B | — |
| Q4 25 | $4.0B | $2.9B | ||
| Q3 25 | $4.0B | $4.4B | ||
| Q2 25 | $5.3B | $4.5B | ||
| Q1 25 | $5.2B | $4.4B | ||
| Q4 24 | $5.2B | $4.3B | ||
| Q3 24 | $7.3B | $4.6B | ||
| Q2 24 | $7.2B | $4.5B | ||
| Q1 24 | $7.1B | $4.7B |
| Q4 25 | $21.7B | $8.5B | ||
| Q3 25 | $22.2B | $10.1B | ||
| Q2 25 | $23.7B | $10.1B | ||
| Q1 25 | $23.2B | $9.8B | ||
| Q4 24 | $22.9B | $9.6B | ||
| Q3 24 | $25.9B | $11.2B | ||
| Q2 24 | $25.8B | $10.4B | ||
| Q1 24 | $26.0B | $10.6B |
| Q4 25 | 2.81× | — | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.14× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.54× | — | ||
| Q1 24 | 1.56× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $252.0M | $175.4M |
| Free Cash FlowOCF − Capex | $168.0M | $148.6M |
| FCF MarginFCF / Revenue | 7.6% | 13.4% |
| Capex IntensityCapex / Revenue | 3.8% | 2.4% |
| Cash ConversionOCF / Net Profit | 18.00× | — |
| TTM Free Cash FlowTrailing 4 quarters | $803.0M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $252.0M | $175.4M | ||
| Q3 25 | $447.0M | $51.7M | ||
| Q2 25 | $410.0M | $75.9M | ||
| Q1 25 | $37.0M | $-64.5M | ||
| Q4 24 | $494.0M | $312.6M | ||
| Q3 24 | $79.0M | $42.2M | ||
| Q2 24 | $292.0M | $9.5M | ||
| Q1 24 | $101.0M | $-1.4M |
| Q4 25 | $168.0M | $148.6M | ||
| Q3 25 | $383.0M | $29.8M | ||
| Q2 25 | $317.0M | $56.7M | ||
| Q1 25 | $-65.0M | $-90.0M | ||
| Q4 24 | $389.0M | $274.9M | ||
| Q3 24 | $-9.0M | $15.1M | ||
| Q2 24 | $187.0M | $-18.9M | ||
| Q1 24 | $-36.0M | $-26.5M |
| Q4 25 | 7.6% | 13.4% | ||
| Q3 25 | 15.8% | 2.9% | ||
| Q2 25 | 12.5% | 5.4% | ||
| Q1 25 | -2.7% | -8.6% | ||
| Q4 24 | 16.4% | 24.2% | ||
| Q3 24 | -0.3% | 1.4% | ||
| Q2 24 | 7.1% | -1.8% | ||
| Q1 24 | -1.4% | -2.4% |
| Q4 25 | 3.8% | 2.4% | ||
| Q3 25 | 2.6% | 2.1% | ||
| Q2 25 | 3.7% | 1.8% | ||
| Q1 25 | 4.3% | 2.4% | ||
| Q4 24 | 4.4% | 3.3% | ||
| Q3 24 | 3.3% | 2.5% | ||
| Q2 24 | 4.0% | 2.7% | ||
| Q1 24 | 5.2% | 2.3% |
| Q4 25 | 18.00× | — | ||
| Q3 25 | — | 6.89× | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 1.88× | — | ||
| Q1 24 | 0.83× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CE
| Engineered Materials | $1.3B | 58% |
| Acetyl Chain | $940.0M | 43% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
